This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bauskin, A. R. Articles by Breit, S. N. Search for Related Content PubMed PubMed Citation Articles by Bauskin, A. R. Articles by Breit, S. N. Related Collections Tumor Biology Tumor Biology: Inflammation and Immune Escape Cancer Immunology: Innate Immunity

Role of Macrophage Inhibitory Cytokine-1 in Tumorigenesis and Diagnosis of Cancer

Centre for Immunology, St. Vincent's Hospital and University of New South Wales, Sydney, Australia

Requests for reprints: Samuel N. Breit and Asne R. Bauskin, Centre for Immunology, St. Vincent's Hospital, Sydney, New South Wales, Australia. Phone: 612-8382-3700; Fax: 612-8382-2830; E-mail: a.bauskin{at}cfi.unsw.edu.au; s.breit{at}cfi.unsw.edu.au.

Macrophage inhibitory cytokine-1 (MIC-1), a transforming growth factor-ß superfamily cytokine, is involved in tumor pathogenesis, and its measurement can be used as a clinical tool for the diagnosis and management of a wide range of cancers. Although generally considered to be part of the cell's antitumorigenic repertoire, MIC-1 secretion, processing, and latent storage suggest a complex, dynamic variability in MIC-1 bioavailability in the tumor microenvironment, potentially modulating tumor progression and invasiveness. (Cancer Res 2006; 66(10): 4983-5)

This article has been cited by other articles:

				D. A. Brown, F. Lindmark, P. Stattin, K. Balter, H.-O. Adami, S. L. Zheng, J. Xu, W. B. Isaacs, H. Gronberg, S. N. Breit, et al. Macrophage Inhibitory Cytokine 1: A New Prognostic Marker in Prostate Cancer Clin. Cancer Res., November 1, 2009; 15(21): 6658 - 6664. [Abstract] [Full Text] [PDF]

				L. Zhao, B. Y. Lee, D. A. Brown, M. P. Molloy, G. M. Marx, N. Pavlakis, M. J. Boyer, M. R. Stockler, W. Kaplan, S. N. Breit, et al. Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling Cancer Res., October 1, 2009; 69(19): 7696 - 7703. [Abstract] [Full Text] [PDF]

				Q. Ding, T. Mracek, P. Gonzalez-Muniesa, K. Kos, J. Wilding, P. Trayhurn, and C. Bing Identification of Macrophage Inhibitory Cytokine-1 in Adipose Tissue and Its Secretion as an Adipokine by Human Adipocytes Endocrinology, April 1, 2009; 150(4): 1688 - 1696. [Abstract] [Full Text] [PDF]

				M. Lankeit, T. Kempf, C. Dellas, M. Cuny, H. Tapken, T. Peter, M. Olschewski, S. Konstantinides, and K. C. Wollert Growth Differentiation Factor-15 for Prognostic Assessment of Patients with Acute Pulmonary Embolism Am. J. Respir. Crit. Care Med., May 1, 2008; 177(9): 1018 - 1025. [Abstract] [Full Text] [PDF]

				K.-K. Kim, J. J. Lee, Y. Yang, K.-H. You, and J.-H. Lee Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells Carcinogenesis, April 1, 2008; 29(4): 704 - 712. [Abstract] [Full Text] [PDF]

				C.-Y. Huang, T. M. Beer, C. S. Higano, L. D. True, R. Vessella, P. H. Lange, M. Garzotto, and P. S. Nelson Molecular Alterations in Prostate Carcinomas that Associate with In vivo Exposure to Chemotherapy: Identification of a Cytoprotective Mechanism Involving Growth Differentiation Factor 15 Clin. Cancer Res., October 1, 2007; 13(19): 5825 - 5833. [Abstract] [Full Text] [PDF]

				T. Kempf, R. Horn-Wichmann, G. Brabant, T. Peter, T. Allhoff, G. Klein, H. Drexler, N. Johnston, L. Wallentin, and K. C. Wollert Circulating Concentrations of Growth-Differentiation Factor 15 in Apparently Healthy Elderly Individuals and Patients with Chronic Heart Failure as Assessed by a New Immunoradiometric Sandwich Assay Clin. Chem., February 1, 2007; 53(2): 284 - 291. [Abstract] [Full Text] [PDF]